Technologies for preserving kidney function in patients with chronic kidney disease and hyperuricemia

Authors

  • D.D. Ivanov Shupyk National University of Public Health of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0003-2609-0051
  • T.B. Bevzenko Shupyk National University of Public Health of Ukraine, Kyiv, Ukraine
  • S.V. Kushnirenko Shupyk National University of Public Health of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0001-5518-7210
  • S.A. Rotova Shupyk National University of Public Health of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.10.1.2021.227201

Keywords:

chronic kidney disease, hyperuricemia, renal replacement therapy

Abstract

The prevalence of chronic kidney disease (CKD) and hyperuricemia is increasing globally. The steady increase in the number of patients with impaired renal function associated with diabetes mellitus, arterial hypertension, and an increase in life expectancy ultimately leads to significant costs associated with the need to use expensive methods of renal replacement therapy. The main task for physicians is the timely determination and slowing down of the progression of CKD, and renoprotection. Hyperuricemia is considered an independent risk factor for the onset and progression of the disease, in addition to the traditional microalbuminuria and decreased glomerular filtration rate. The urgency of detecting hyperuricemia is due to the possibility of its further correction to improve the prognosis of the disease and delay the end stage of CKD, improve the quality of life and reduce the cost of treatment of patients. A decrease in the total pool of uric acid in the body helps to minimize the risk of arthropathy and nephrolithiasis, exacerbation of gout, progression of renal failure and other complications. However, despite hundreds of published clinical studies on the diagnosis and treatment of patients with CKD, the quality of care remains suboptimal. The article presents versatile technologies of preserving renal function in patients with CKD and hyperuricemia, which require improvement.

References

Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993 Jun;14(6):615-631. doi:10.1016/0891-5849(93)90143-i.

Oh TR, Choi HS, Kim CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019 Apr 30;9(1):6681. doi:10.1038/s41598-019-43241-3.

Kim CS, Jin DC, Yun YC, Bae EH, Ma SK, Kim SW. Relationship between serum uric acid and mortality among hemodialysis patients: Retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 2017 Dec;36(4):368-376. doi:10.23876/j.krcp.2017.36.4.368.

Chini LSN, Assis LIS, Lugon JR. Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers. Braz J Med Biol Res. 2017 Aug 7;50(9):e6048. doi:10.1590/1414-431X20176048.

Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007 Aug;50(2):239-247. doi:10.1053/j.ajkd.2007.05.013.

Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009 May;53(5):796-803. doi:10.1053/j.ajkd.2008.12.021.

Mount DB. Hypouricemia: сauses and clinical significance. Available from: https://www.uptodate.com/contents/hypouricemia-causes-and-clinical-significance. Accessed: September 14, 2020.

Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res. 2016 Nov;113(Pt A):600-609. doi:10.1016/j.phrs.2016.09.040.

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. doi:10.1016/S0140-6736(16)31012-1.

Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011 Dec;80(12):1258-1270. doi:10.1038/ki.2011.368.

Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017 Jul 6;2(2):e000380. doi:10.1136/bmjgh-2017-000380.

Levin A, Stevens PE, Bilous RW, et al. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1-150. doi:10.1038/kisup.2012.73.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):43-100.

National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians (UK); 2008. 237 p.

Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008 Nov 10;168(20):2212-2218. doi:10.1001/archinte.168.20.2212.

Lemley KV. Glomerular pathology and the progression of chronic kidney disease. Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1385-1388. doi:10.1152/ajprenal.00099.2016.

Sharaf El Din UA, Salem MM, Abdulazim DO. Stop chronic kidney disease progression: Time is approaching. World J Nephrol. 2016 May 6;5(3):258-273. doi:10.5527/wjn.v5.i3.258.

Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F145-161. doi:10.1152/ajprenal.00164.2016.

Sarvepalli PS, Fatima M, Quadri AK, et al. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1050-1056. doi:10.4103/1319-2442.243953.

Roughley M, Sultan AA, Clarson L, et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther. 2018 Oct 30;20(1):243. doi:10.1186/s13075-018-1746-1.

Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12):2888-2897. doi:10.1097/01.asn.0000034910.58454.fd.

Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan;47(1):51-59. doi:10.1053/j.ajkd.2005.10.006.

Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 2015 Oct;83(4):475-482. doi:10.1111/cen.12673.

Bakan A, Oral A, Elcioglu OC, et al. Hyperuricemia is associated with progression of IgA nephropathy. Int Urol Nephrol. 2015 Apr;47(4):673-678. doi:10.1007/s11255-015-0939-7.

Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013 Feb;28(2):380-385. doi:10.1093/ndt/gfs417.

Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation. 2014 May 27;97(10):1066-1071. doi:10.1097/01.TP.0000440952.29757.66.

Lanaspa MA, Andres-Hernando A, Kuwabara M. Uric acid and hypertension. Hypertens Res. 2020;43:832-834.

Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019 Aug 24;9(8):e026677. doi:10.1136/bmjopen-2018-026677.

McLean RM. The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout. Ann Intern Med. 2017 Jan 3;166(1):73-74. doi:10.7326/M16-2426.

Bonino B, Leoncini G, Russo E, Pontremoli R, Viazzi F. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020 Aug;33(4):715-724. doi:10.1007/s40620-020-00702-7.

Savyc'ka LM. Rol' stanu funkcional'nogo nyrkovogo rezervu, rivniv sechovoi' kysloty ta magniju u progresuvanni hronichnoi' hvoroby nyrok: diss. kand. med. nauk. med. nauk [The role of functional renal reserve, uric acid and magnesium levels in the progression of chronic kidney disease. PhD in med sci diss.]. Zaporizhzhia; 2020. 21 p. (in Ukrainian).

Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020 Oct;87(5):395-404. doi:10.1016/j.jbspin.2020.05.002.

Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. Circ J. 2021 Jan 25;85(2):130-138. doi:10.1253/circj.CJ-20-0406.

Vargas-Santos AB, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017 Sep;70(3):422-439. doi:10.1053/j.ajkd.2017.01.055.

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760. doi:10.1002/acr.24180.

Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi:10.1136/annrheumdis-2016-209707.

Qaseem A, McLean RM, Starkey M, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):52-57. doi:10.7326/M16-0569.

Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. doi:10.7326/M16-0570.

Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017 Jul 1;56(7):e1-e20. doi:10.1093/rheumatology/kex156.

Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham JM. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018 May 1;57(5):826-830. doi:10.1093/rheumatology/kex521.

Published

2021-04-16

Issue

Section

Cover story